Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-07-18, Stock:ABBV, The news for the past five days is as follows:
2019-07-11: NEWS1: FDA Accepts Neurocrine's NDA for Parkinson's Disease Drug.NEWS2: FDA Accepts Neurocrine's NDA for Parkinson's Disease Drug.NEWS3: ITOT, ABBV, GE, AXP: Large Outflows Detected at ETF.NEWS4: ITOT, ABBV, GE, AXP: Large Outflows Detected at ETF.NEWS5: FDA Accepts Neurocrine's NDA for Parkinson's Disease Drug.NEWS6: J&J (JNJ) to Kick-Start Pharma Q2 Earnings: A Beat in Store?.NEWS7: J&J (JNJ) to Kick-Start Pharma Q2 Earnings: A Beat in Store?.NEWS8: AbbVie Inc. (ABBV) Ex-Dividend Date Scheduled for July 12, 2019.NEWS9: AbbVie Inc. (ABBV) Ex-Dividend Date Scheduled for July 12, 2019.NEWS10: AbbVie to Host Second-Quarter 2019 Earnings Conference Call.NEWS11: J&J (JNJ) to Kick-Start Pharma Q2 Earnings: A Beat in Store?.NEWS12: 2 Falling Pharma Stocks Whose Star May Rise in 2019.
2019-07-12: NEWS1: Health companies start reporting earnings next week: Here are 3 things to keep in mind.
2019-07-15: NEWS1: AbbVie (ABBV) Gains But Lags Market: What You Should Know.NEWS2: AbbVie Acquires Mavupharma For Undisclosed Amount.NEWS3: AbbVie Enhances Early Stage Oncology Pipeline with Acquisition of Mavupharma.
2019-07-16: NEWS1: AbbVie Buys Allergan for $63 Billion.NEWS2: AbbVie (ABBV) Acquires Mavupharma to Boost Cancer Portfolio.NEWS3: AbbVie (ABBV) Acquires Mavupharma to Boost Cancer Portfolio.NEWS4: Commit To Purchase AbbVie At $40, Earn 3.2% Using Options.NEWS5: Commit To Purchase AbbVie At $40, Earn 3.2% Using Options.NEWS6: J&J (JNJ) Beats on Q2 Earnings, Ups 2019 Sales Growth View.NEWS7: J&J (JNJ) Beats on Q2 Earnings, Ups 2019 Sales Growth View.NEWS8: AbbVie (ABBV) Acquires Mavupharma to Boost Cancer Portfolio.NEWS9: J&J (JNJ) Beats on Q2 Earnings, Ups 2019 Sales Growth View.NEWS10: Allergan Stock Won’t Rise Much More, Analyst Says, in Looking at Deal With AbbVie.
2019-07-17: NEWS1: AbbVie (ABBV) is an Incredible Growth Stock: 3 Reasons Why.NEWS2: AbbVie (ABBV) is an Incredible Growth Stock: 3 Reasons Why.NEWS3: AbbVie (ABBV) Upgraded to Buy: Here's What You Should Know.NEWS4: AbbVie (ABBV) Upgraded to Buy: Here's What You Should Know.NEWS5: Health care 'Cadillac Tax' repeal bill up for vote Wednesday.NEWS6: Should Value Investors Buy AbbVie (ABBV) Stock?.NEWS7: AbbVie (ABBV) Upgraded to Buy: Here's What You Should Know.NEWS8: AbbVie (ABBV) is an Incredible Growth Stock: 3 Reasons Why.

Answer: Decrease